Outlook Therapeutics’ (OTLK) Buy Rating Reaffirmed at BTIG Research

BTIG Research reiterated their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a report issued on Friday morning, Benzinga reports. The brokerage currently has a $50.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on OTLK. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research note on Thursday, August 15th. Chardan Capital reiterated a “buy” rating and set a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday, August 16th. Finally, Ascendiant Capital Markets cut their price objective on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $48.20.

Outlook Therapeutics Price Performance

Shares of NASDAQ:OTLK opened at $5.31 on Friday. The company has a market capitalization of $125.63 million, a price-to-earnings ratio of -0.50 and a beta of 0.62. Outlook Therapeutics has a 1 year low of $4.61 and a 1 year high of $18.00. The business’s 50-day moving average is $6.40 and its 200-day moving average is $7.40.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.23. Analysts anticipate that Outlook Therapeutics will post -3.63 EPS for the current year.

Insider Buying and Selling

In other news, CFO Lawrence A. Kenyon purchased 5,000 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was purchased at an average price of $5.69 per share, with a total value of $28,450.00. Following the completion of the purchase, the chief financial officer now directly owns 5,946 shares in the company, valued at approximately $33,832.74. This trade represents a 500.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in shares of Outlook Therapeutics during the 2nd quarter valued at $75,000. Squarepoint Ops LLC purchased a new stake in Outlook Therapeutics during the second quarter valued at about $232,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Outlook Therapeutics during the second quarter valued at about $303,000. LVW Advisors LLC purchased a new position in shares of Outlook Therapeutics in the second quarter worth about $352,000. Finally, Rosalind Advisors Inc. lifted its stake in shares of Outlook Therapeutics by 44.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock valued at $3,321,000 after acquiring an additional 138,225 shares during the last quarter. 11.20% of the stock is currently owned by institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.